26 Apr 2021 (Last Updated April 26th, 2021 16:03)
Health Canada has accepted for review the first portion of the rolling submission by Medicago for its plant-derived adjuvanted Covid-19 vaccine candidate.
Share Article
The company has received regulatory approval to commence the Phase III portion of its Phase II/III clinical development in Canada, the US, the UK and Brazil. Credit: Raghavendra V Konkathi / Unsplash.
Health Canada has accepted for review the first portion of the rolling submission by Medicago for its plant-derived adjuvanted Covid-19 vaccine candidate.
The vaccine candidate uses coronavirus-like-particle (CoVLP) technology and has recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) administered along with GlaxoSmithKline’s (GSK) pandemic adjuvant.
Health Canada initiates the review of the rolling submission for the first Canadian-based COVID-19 vaccine candidate newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Studio Romantic/Shutterstock
Health Canada has begun a rolling review of the first Canadian-based COVID-19 vaccine candidate.
Medicago, a biopharmaceutical company headquartered in Quebec City, announced on April 23 that Health Canada had accepted its submission for a rolling review of its vaccine.
The company’s COVID-19 vaccine uses “virus-like-particles,” a technology that mimics the structure of the coronavirus but doesn’t actually contain any genetic material from it, making it non-infectious.
It also contains an adjuvant from pharmaceutical company GlaxoSmithKline, which helps create a “stronger and longer-lasting” immunity than the vaccine would alone.
Medicago’s COVID-19 vaccine requires two doses which are administered 21 days apart.